UPB

Upstream Bio, Inc. NASDAQ Listed Oct 11, 2024

Healthcare ·Biotechnology ·US · upstreambio.com

$8.99

Mkt Cap $489.2M

52w Low $7.25 6.6% of range 52w High $33.68

50d MA $9.10 200d MA $18.85

P/E (TTM) -3.5x

EV/EBITDA -8.5x

P/B 1.5x

Debt/Equity 0.0x

ROE -42.2%

P/FCF -11.0x

RSI (14) —

ATR (14) —

Beta 1.83

50d MA $9.10

200d MA $18.85

Avg Volume 1.3M

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

SIC Code

2834

CIK (SEC)

2022626

Phone

781 208 2466

890 Winter Street · Waltham, MA 02451 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
May 8, 2026	BMO	—	—	—	8.99	-1.2%	+1.1%	—	—	—	—	—
May 7, 2026	BMO	—	—	—	9.19	-0.5%	-2.2%	—	—	—	—	—
Mar 26, 2026	BMO	-0.73	-0.79	-8.2%	9.79	-10.9%	-11.4%	-11.4%	-10.3%	-8.1%	-4.9%	—
Nov 5, 2025	BMO	-0.78	-0.63	+19.2%	23.97	+0.1%	-1.3%	-1.3%	-4.2%	-2.0%	-0.8%	—
Aug 6, 2025	BMO	-0.61	-0.74	-21.3%	16.72	+2.0%	-5.3%	-5.3%	-4.3%	-0.8%	+4.7%	—
May 6, 2025	BMO	-0.49	-0.51	-4.1%	8.21	-0.7%	+4.5%	+4.5%	+7.7%	+7.4%	+15.7%	—
Mar 13, 2025	BMO	-0.56	-1.59	-183.9%	9.06	+3.0%	+6.1%	+6.1%	+8.9%	-0.2%	-5.6%	—
Nov 7, 2024	BMO	-0.54	-6.96	-1200.3%	27.02	+1.5%	-3.1%	-3.1%	-0.8%	-2.4%	-4.1%	—
Dec 31, 2023	BMO	—	-0.14	—	—	—	—	—	—	—	—	—
Sep 30, 2023	BMO	—	-0.09	—	—	—	—	—	—	—	—	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 27	Evercore ISI	Downgrade	Outperform → In Line	—	$9.79	$8.72	-10.9%	-11.4%	-10.3%	-8.1%	-4.9%	-3.0%

Data updated apr 27, 2026 6:54am · Source: massive.com